The use of telmisartan in patients with refractory arterial hypertension and obesity

Aim. To evaluate the effectiveness of telmisartan as a component of triple antihypertensive therapy in patients with obesity and refractory arterial hypertension.

Material and methods. The study included 30 patients with obesity and refractory arterial hypertension. All patients received an angiotensin II receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACE inhibitor) in an adequate dosage as part of a triple antihypertensive therapy that also includes a calcium antagonist and thiazide diuretic. Participants were randomly divided into two equal groups. In the main group, telmisartan (Dr. Reddy’s Laboratories) was prescribed at a dosage of 80 mg/day instead of the previously taken ARB or ACE inhibitor. In the control group, patients continued to receive a previously prescribed ARB or an ACE inhibitor. The primary end point was a decrease in mean daily systolic and/or diastolic blood pressure (SBP and DBP) according to 24-hour blood pressure monitoring at 10 mm Hg and more than 20 weeks after the start of the study. The secondary end point was a decrease in the concentration of inflammatory markers and an increase in the level of adiponectin by 15%.

Results. After 20 weeks, in the telmisartan group, we noted a significant decrease in the average daily SBP and DBP: in the main group from 145,9±5,4/95,6±4,8 mm Hg to 134,8±3,0/84,9±4,2 mm Hg, in the control group with 147,2±4,9/96,4±5,6 mm Hg to 142,4±4,3/96,9±62 mm Hg. We also determined an increase in the serum adiponectin concentration from 9,3±5,6 μg/ml to 13,4±6,6 μg/ml in the main group and a decrease from 8,8±5,2 μg/ml to 8,6±5,6 μg/ml in the control group, as well as a decrease in the concentration of highly sensitive C-reactive protein (main group from 8,8±3,0 to 6,0±2,8 mg/l and the control group from 7,4±3,8 to 6,9±4,9 mg/l) and interleukin-6 (main group from 16,2±6,1 to 12,3±2,8 pg/ml, control group from 22,5±4,2 to 19,9±5,2 pg/ml).

Conclusion. Telmisartan can be considered as a drug of choice as part of multi-component therapy in the treatment of patients with obesity and refractor arterial hypertension.

1. Obesity and overweight. WHO Fact sheets. https://www.who.int/news-room/factsheets/detail/obesity-and-overweight (16 February 2018).

2. Zhernakova YV, Zheleznova EA, Chazova IE, et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study — ESSE-RF. Therapeutic archive. 2018;90(10):14-22. (In Russ). doi:10.26442/terarkh201890104-22.

3. Romantsova TI. Epidimiology of obesity. Obvious and probable causes. Obesity and metabolism. 2011;1:5-9. (In Russ).

4. Hales CM, Fryar CD, Carroll MD, et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. Jama. 2018;319(16):1723-5. doi:10.1001/jama.2018.3060.

5. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief. 2017;(288):1-8.

6. Jensen MD, Ryan DH, Donato KA, et al. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Obesity (Silver Spring). 2014;22 Suppl 2:S5-39. doi:10.1002/oby.20821.

7. Dombrovskiy VS, Khachatryan GR. Comparison of recommended screening programs in the United States, Canada, the Netherlands and Germany. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016;9(4):46-53. (In Russ.) doi:10.17749/2070-4909.2016.9.4.046-053.

8. Karbowska J, Kochan Z. Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol. 2006;57(6):103-13.

9. Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesityassociated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):1-10. doi:10.1007/s11154-013-9271-7.

10. Lefils-Lacourtablaise J, Socorro M, Géloën A, et al. The eicosapentaenoic acid metabolite 15-deoxy-δ(12,14)-prostaglandin J3 increases adiponectin secretion by adipocytes partly via a PPARγ-dependent mechanism. PLoS One. 2013;8(5):e63997. doi:10.1371/journal.pone.0063997.

11. Chigurupati S, Dhanaraj SA, Balakumar P. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance. Eur J Pharmacol. 2015;755:50-7. doi:10.1016/j.ejphar.2015.02.043.

12. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15(1):14-33. doi:10.1111/jch.12049.

13. Sueta D, Kataoka K, Koibuchi N, et al. Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome — the critical role of angiotensin II. J Am Heart Assoc. 2013;2(3):e000035. doi:10.1161/JAHA.113.000035.

14. Imaizumi S, Miura S, Yahiro E, et al. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des. 2013;19(17):3002-8.

15. Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809-48. doi:10.1124/pr.112.007278.

16. Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res. 2005;28(7):593-600. doi:10.1291/hypres.28.593.

17. Taguchi I, Inoue T, Kikuchi M, et al. Pleiotropic effects of ARB on dyslipidemia. Curr Vasc Pharmacol. 2011;9(2):129-35.

18. Deneka IE, Rodionov AV, Fomin VV. Treatment of hypertension in obese patients: focus on telmisartan. Cardiovascular Therapy and Prevention. 2018;17(6):69-76. (In Russ). doi:10.15829/1728-8800-2018-6-69-76.

19. Mulrow CD, Chiquette E, Angel L, et al. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev. 2000;(2):CD00048.

20. Dremova NB, Yaroshenko NP, Afanaseva NI, et al. Monitoring of consumer attitudes to medicines. pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016;9(3):49-52. (In Russ). doi:10.17749/2070-4909.2016.9.3.049-052.

21. Tolkacheva DG, Torgov AV, Margazova AS. International approaches to the government price control over generics and biosimilars: a review. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2017;10(4):15-24. (In Russ).